Search
Human papillomavirus type 45 L1 capsid protein antigen
go.drugbank.com/drugs/DB10312ApprovedInvestigationalHuman papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNESynonyms: L1 protein, Human papillomavirus type 45 Vaccine, Human papillomavirus type 45 L1 capsid protein antigenHuman papillomavirus type 58 L1 capsid protein antigen
go.drugbank.com/drugs/DB10314ApprovedInvestigationalHuman papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNESynonyms: L1 protein, Human papillomavirus type 58 Vaccine, Human papillomavirus type 58 L1 capsid protein antigenUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalCOPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Metyrosine
go.drugbank.com/drugs/DB00765ApprovedInvestigationalIt is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.
Synonyms: (–)-α-methyl-L-tyrosine, α-methyl-L-p-tyrosineBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnIt is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Synonyms: .-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINERegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.
Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IbSynonyms: 2-amino-N-(2,6-dimethylphenyl)propanamide, 2-Amino-N-(2,6-dimethylphenyl)propionamidEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalEfinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. … It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Etelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.